Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.
BlackRock Health Sciences Opps R BHSRX
- NAV / 1-Day Return 68.59 / +0.79 %
- Total Assets 8.3 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.460%
- Distribution Fee Level Average
- Share Class Type Retirement, Medium
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 100
- Status Open
- TTM Yield —
- Turnover 29%
USD | NAV as of Jul 06, 2024 | 1-Day Return as of Jul 06, 2024, 12:43 AM GMT+0
Morningstar’s Analysis BHSRX
Will BHSRX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 49.0
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 9.86 | 820.4 Mil | Healthcare |
UnitedHealth Group Inc | 7.78 | 647.8 Mil | Healthcare |
Boston Scientific Corp | 5.56 | 462.5 Mil | Healthcare |
AbbVie Inc | 4.83 | 402.1 Mil | Healthcare |
Merck & Co Inc | 4.29 | 357.4 Mil | Healthcare |
Amgen Inc | 3.79 | 315.4 Mil | Healthcare |
Thermo Fisher Scientific Inc | 3.53 | 293.8 Mil | Healthcare |
Danaher Corp | 3.35 | 279.1 Mil | Healthcare |
Elevance Health Inc | 3.04 | 252.6 Mil | Healthcare |
Intuitive Surgical Inc | 2.93 | 244.2 Mil | Healthcare |